New Study Claims Pfizer Vaccine Recipients Face 37% Higher Risk of Death Than Moderna Recipients

A recent study has sparked significant discussion in the medical and public health communities, alleging that individuals who received the Pfizer-BioNTech COVID-19 vaccine face a 37% higher risk of death compared to those who received the Moderna vaccine. The study, which analysed data from 1.47 million adults in Florida, was conducted by MIT researcher Retsef Levi and Florida Surgeon General Joseph Ladapo. The findings point to increased risks of all-cause mortality, cardiovascular issues, and COVID-19-related complications among Pfizer recipients.

Study Overview

The study focused on a large cohort of Florida adults, comparing outcomes between those who received the Pfizer-BioNTech mRNA vaccine and those who received the Moderna mRNA vaccine. Both vaccines were widely administered during the COVID-19 pandemic as part of global vaccination efforts to curb the spread of the virus. However, the researchers claim their analysis revealed stark differences in outcomes between the two groups.

According to the study’s findings, recipients of the Pfizer vaccine experienced a 37% higher risk of death compared to their Moderna counterparts. The researchers also noted elevated risks of cardiovascular events, such as heart attacks or strokes, and increased COVID-19-related complications among the Pfizer group. The study attributes these differences to potential variations in the vaccines’ formulations, immune responses, or other underlying factors not specified in the summary.

Researchers Involved

The study was led by Retsef Levi, a professor at the Massachusetts Institute of Technology (MIT) who specialises in operations management and has been involved in analysing health policy data during the pandemic. Levi collaborated with Joseph Ladapo, Florida’s Surgeon General, who has been controversial in public health discussions. Ladapo, appointed by Governor Ron DeSantis, has previously questioned the safety and efficacy of COVID-19 vaccines and has advocated for alternative approaches to managing the pandemic, such as focusing on natural immunity and treatments like monoclonal antibodies.

Implications

The findings, if validated, could have significant implications for public health policy and vaccine recommendations. Both Pfizer and Moderna vaccines have been hailed as highly effective in preventing severe COVID-19 outcomes, with clinical trials and real-world data showing substantial reductions in hospitalisations and deaths. However, differences between the two vaccines have been noted in prior studies, particularly regarding side effects like myocarditis (inflammation of the heart muscle), which has been more commonly associated with the Pfizer vaccine in specific populations, such as young males.

The study’s summary is available at http://www.thefocalpoints.com for more information.